Some TNBC patients, for example, lumen-type androgen This study was to investigate the prognostic role of p53 and Ki-67 in 156 cases of TNBC patients. Triple negative breast cancer metastasis prognosis - Triple negative breast cancer is considered a highly diverse group of cancer, in general, a positive disease related to poor survival. Triple-negative breast cancer (TNBC) is an aggressive subgroup of breast cancer lack of effective target therapy. Good response to NAC was associated with p53 expression. Basal-like breast cancers are likely to benefit from chemotherapy. Understanding more about the chemical and genetic makeup of your cancer may help doctors choose the most effective treatment for your specific cancer. Breast cancers are ER-positive, HER2-positive, or triple negative. Also ki67, TLI and SLI showed association with triple negative tumor subtype (P-value 0.011, 0.002 and 0.014). Hormone receptor status can change during disease progression Breast cancer that starts as an ER+ and/or PR+ primary tumor and converts to triple negative status when the cancer recurs has a worse prognosis than disease that is consistently ER+ and/or PR+. Background: The purpose of the study was to analyze Ki-67 and Cyclin D1 expression in subtypes of triple negative breast cancer (TNBC) with different androgen profiles.Methods: Tissues of 60 patients with verified TNBC (T1N1M0/T2N0M0, ER-/PR-/Her2-) were studied. The aim of the current study was to investigate the expression of the proliferation antigen, Ki67, in triple‑negative breast cancer (TNBC) and its correlation with clinicopathological factors. Immunohistochemical staining was performed with antibodies to androgen receptors (AR), CK5/6, Ki-67… This type, which is also called triple-negative breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Learn more from experts at WebMD. MKI67 encodes for Ki-67, ... by the current debate about the use of specific immunohistochemical markers for PD-L1 assessment in patients with triple-negative (ie, ER-negative, progesterone receptor-negative, and HER2-negative) disease to identify recipients for checkpoint inhibitors (14, 15). Breast cancer with a high Ki-67 value responds better to chemotherapy but is associated with lower relapse-free (RFS) and overall survival rates. On the other hand, we found an even high ki67 in these two subtypes of breast cancer; more than 90% of her2neu and triple negative breast cancers had ki67 > 14% in our study. Logistic regression analysis was used to examine the association between clinical parameters and recurrence. reported a high ki67 index (> 15%) in 34% & 60% of her2neu and triple negative breast cancer respectively . While prognosis is, on average, poorer than with hormone receptor or human epidermal growth factor receptor 2 (HER2) positive tumors, triple-negative breast cancer is a very heterogeneous (diverse) disease. Soliman et al. Recent gene expression Microarray research has revealed at least six sub-types. Questions about the survival rate and recurrence rate are very common when someone is diagnosed with triple-negative breast cancer (TNBC). e12552. The type of breast cancer you have determines the type of medication you take. 142 Background: Triple-negative breast cancer (TNBC) tends to produce a poor prognosis because of aggressive tumor biology and lack of targeted agents. Background: Ki-67 is a widely used marker of tumor proliferation, but the prognostic value of ki-67 in triple-negative breast cancer (TNBC) has not been comprehensively reviewed. Univariate and multivariate analyses were used to examine the … Ki-67 exceeds 35% in the majority of triple negative tumors.